The global pyrogen market is growing at 12.5% CAGR owing to the increased focus on personalized medicine, rising R&D in the pharmaceutical and biotech industries, mounting prominence of chronic diseases, increasing awareness about food safety, increasing prevalence of chronic diseases, and the growing frequency of pandemics. Moreover, the increasing demand for pyrogen in vitro assays to identify the presence and concentration of bacterial endotoxins via Limulus amebocyte lysate (LAL) testing in biological products and drugs will propel the growth of the market.

Pyrogen testing protocol is necessary and is adopted in pharmaceutical, biotechnological, and medical devices organizations to check the absence of toxic in molecular products and medical devices, thereby ensuring product safety, competence, and adoption of sanitized resources.

Lonza Sales AG has entered into a strategic partnership with Sanquin Reagents BV to commercialize an array of specialized reagents for pyrogen testing of parenteral pharmaceuticals and medical devices via monocyte activation test (MAT).

The COVID-19 crisis has impelled the government to provide support for vaccine development, resulting in the need for pyrogen testing products for COVID-19 research. Nevertheless, manufacturing of vaccines is anticipated to increase owing to the infectious coronavirus, bacterial endotoxin testing will play a significant role in quality assurance measures to ensure patient safety.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/pyrogen-testing-market/request-sample

Based on product, kits and reagents dominates the market in 2020 owing to the increasing preference for kit-based testing in the world and the continuous requirement of kits and reagents.

Based on test type, LAL tests are anticipated to have the largest share owing to the rising demand for animal-free detection tests, high reliability, and reproduction during detection. Moreover, robust growth in the pharmaceutical and biotech industries, rising demand for medical devices, growing health standards, and increasing drug pipelines will propel the growth of the LAL segment in the pyrogen testing market.

North America dominates the pyrogen testing market owing to increasing expenditure of R&D activities in the pharmaceutical and biotech industry, growing pharmaceutical drug pipelines, increasing number of drug approvals, and emphasis by consumers on food safety

The prominent players in the pyrogen testing industry include Associates of Cape Cod, Inc., Merck KGaA, Thermo Fisher Scientific, Inc., GenScript, Charles River Laboratories, Inc., Ellab A/S, Lonza Group, and WUXI Pharmatech (Cayman) Inc.

Source: VynZ Research